{
    "clinical_study": {
        "@rank": "85683", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Control"
            }, 
            {
                "arm_group_label": "orBec", 
                "arm_group_type": "Experimental", 
                "description": "Investigational drug"
            }
        ], 
        "brief_summary": {
            "textblock": "Use of an oral topically-active glucocorticoid with limited side effects may control the\n      gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure."
        }, 
        "brief_title": "Study of orBec\u00ae as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Gastrointestinal Graft vs Host Disease", 
        "condition_browse": {
            "mesh_term": "Graft vs Host Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Receipt of allogeneic hematopoietic cell transplant >100 days prior to consent\n\n          -  Documented cGVHD as defined by the NIH consensus criteria in at least one organ\n             system other than the GI tract (for example, cGVHD of the oral cavity would qualify\n             as a criterion)\n\n          -  Endoscopic findings consistent with GI GVHD\n\n          -  Must be able to swallow tablets\n\n          -  Must be able to read and understand informed consent\n\n          -  Adequate birth control methods for the duration of the study\n\n        Exclusion Criteria:\n\n          -  >500 mL/day of diarrhea on any 1 day within 3 days prior to the first dose of study\n             drug\n\n          -  GI infection\n\n          -  Multi-organ failure or other condition that, in the opinion of the investigator,\n             would compromise the patient's ability to complete the study.\n\n          -  HIV seropositivity\n\n          -  Pregnant or nursing female\n\n          -  Use of any investigational drug to treat chronic GVHD within 28 days of the first\n             dose of study drug\n\n          -  Evidence of recurrent or progressing malignant disorder that was the indication for\n             HCT"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925950", 
            "org_study_id": "BDP-GVHD-08"
        }, 
        "intervention": [
            {
                "arm_group_label": "orBec", 
                "intervention_name": "orBec", 
                "intervention_type": "Drug", 
                "other_name": [
                    "oral BDP", 
                    "oral beclomethasone 17,21-dipropionate"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Beclomethasone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "BDP", 
            "orBec", 
            "GVHD", 
            "beclomethasone dipropionate", 
            "bone marrow transplant", 
            "hematopoietic cell transplant", 
            "HCT", 
            "stem cell transplant", 
            "marrow transplant", 
            "SCT", 
            "beclomethasone 17,21-dipropionate"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07601"
                    }, 
                    "name": "John Theurer Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt-Ingram Cancer Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec\u00ae (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by GVHD in Patients With Chronic GI GVHD", 
        "overall_contact": {
            "last_name": "Adam Rumage", 
            "phone": "609-538-8200"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "GI GVHD symptoms", 
            "safety_issue": "Yes", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925950"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Soligenix", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Soligenix", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}